Cepheid公司推出在免疫抑制患者中监测巨细胞病毒的PCR检测方法

 
一种定量实时多聚酶链反应(PCR)能够快速准确的诊断巨细胞病毒(CMV)，改善免疫抑制患者的治疗。

Smart CMV检测是由Cepheid公司(Sunnyvale, CA, USA)推出用于该公司SmartCycler系统临床诊断用途。该检测已经获得了欧洲体外诊断(IVD)医疗设备标准的CE标记。设计用于CMV病毒负荷的快速检测和定量，这种检测方法能够检测感染但是没有症状、潜伏期感染和再感染的患者。CMV是一种疱疹病毒，是诸如器官移植、艾滋病和癌症等免疫抑制患者感染和死亡的重要原因。
 
PCR Assay Monitors CMV in Immunocompromised Patients
 
A quantitative real-time polymerase chain reaction (PCR) test provides rapid and accurate diagnosis of cytomegalovirus (CMV) and improved management of immunocompromised patients.

The Smart CMV assay was launched by Cepheid (Sunnyvale, CA, USA) for clinical diagnostic use on its SmartCycler system. The assay has received the CE mark under the European Directive for in vitro diagnostic (IVD) medical devices. Intended for rapid detection and quantitation of CMV viral load, the assay monitors patients for infections that can be asymptomatic and lead to latent infection and reinfection. CMV, which is a herpes virus, is a significant cause of infection and mortality among immunocompromised patients, such as organ transplant recipients andAIDS and cancer patients.